The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Open accessAbstract
Purpose: Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie, DPYD*2A) is strongly associated with fluoropyrimidine-induced severe and life-threatening toxicity. This study determined the feasibility, safety, and cost of DPYD*2A genotype–guided dosing. Patients and Methods: Patients intended to be treated with fluoropyrimidine-based chemotherapy were prospectively genotyped for DPYD*2A before start of therapy. Variant allele carriers received an initial dose reduction of ≥ 50% followed by dose titration based on tolerance. Toxicity was the primary end point and was compared with historical controls (ie, DPYD*2A variant allele carriers receiving standard dose described in literature) and with DPYD*2A wild-type patients treated with the standard dose in this study. Secondary end points included a model-based cost analysis, as well as pharmacokinetic and DPD enzyme activity analyses. Results: A total of 2,038 patients were prospectively screened for DPYD*2A, of whom 22 (1.1%) were heterozygous polymorphic. DPYD*2A variant allele carriers were treated with a median dose-intensity of 48% (range, 17% to 91%). The risk of grade ≥ 3 toxicity was thereby significantly reduced from 73% (95% CI, 58% to 85%) in historical controls (n = 48) to 28% (95% CI, 10% to 53%) by genotype-guided dosing (P < .001); drug-induced death was reduced from 10% to 0%. Adequate treatment of genotype-guided dosing was further demonstrated by a similar incidence of grade ≥ 3 toxicity compared with wild-type patients receiving the standard dose (23%; P = .64) and by similar systemic fluorouracil (active drug) exposure. Furthermore, average total treatment cost per patient was lower for screening (€2,772 [$3,767]) than for nonscreening (€2,817 [$3,828]), outweighing screening costs. Conclusion: DPYD*2A is strongly associated with fluoropyrimidine-induced severe and life-threatening toxicity. DPYD*2A genotype–guided dosing results in adequate systemic drug exposure and significantly improves safety of fluoropyrimidine therapy for the individual patient. On a population level, upfront genotyping seemed cost saving.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.
Heggie, G. D., Sommadossi, J., Cross, D. S., Huster, W. J., & Diasio, R. B. (1987) · PubMed · Cited by 722
Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F. L., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Loosveld, O. J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61086-1 · Cited by 630
Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., Kerb, R., Blievernicht, J., Fischer, J., Hofmann, U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4182 · Cited by 393
Rosmarin, D., Palles, C., Church, D., Domingo, E., Jones, A., Johnstone, E., Wang, H., Love, S., Julier, P., Scudder, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1857 · Cited by 256
Kuilenburg, A. B. P., Muller, E. W., Haasjes, J., Meinsma, R., Zoetekouw, L., Waterham, H. R., Baas, F., Richel, D. J., & Gennip, A. H. (2001) · PubMed · Cited by 253
Familial Pyrimidinemia and Pyrimidinuria Associated with Severe Fluorouracil Toxicity
Tuchman, M., Stoeckeler, J. S., Kiang, D. T., OʼDea, R. F., Ramnaraine, M. L. R., & Mirkin, B. L. (1985) · New England Journal of Medicine · doi:10.1056/nejm198507253130407 · Cited by 252
Morel, A., Boisdron-Celle, M., Fey, L., Soulie, P., Craipeau, M. C., Traore, S., & Gamelin, E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0327 · Cited by 236
Raida, M., Schwabe, W., Häusler, P., Kuilenburg, A. B. P., Gennip, A. H., Behnke, D., & Höffken, K. (2001) · PubMed · Cited by 231
McLeod, H. L., Sargent, D. J., Marsh, S., Green, E. M., King, C. R., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Thibodeau, S. N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.7943 · Cited by 216
Deenen, M. J., Tol, J., Burylo, A. M., Doodeman, V. D., de Boer, A., Vincent, A., Guchelaar, H.-J., Smits, P. H. M., Beijnen, J. H., Punt, C. J. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2209 · Cited by 191
Self-citationMattison, L. K., Fourie, J., Desmond, R. A., Modak, A., Saif, M. W., & Diasio, R. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0747 · Cited by 174
Boige, V., Mendiboure, J., Pignon, J.-P., Loriot, M.-A., Castaing, M., Barrois, M., Malka, D., Trégouët, D.-A., Bouché, O., Le Corre, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2106 · Cited by 172
Twelves, C., Glynne‐Jones, R., Cassidy, J., Schüller, J., Goggin, T. K., Roos, B., Banken, L., Utoh, M., Weidekamm, E., & Reigner, B. G. (1999) · PubMed · Cited by 155
Terrazzino, S., Cargnin, S., Re, M. D., Danesi, R., Canonico, P. L., & Genazzani, A. A. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.116 · Cited by 146
Braun, M. S., Richman, S. D., Thompson, L. C., Daly, C. L., Meade, A. M., Adlard, J., Allan, J. M., Parmar, M., Quirke, P., & Seymour, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6283 · Cited by 128
Offer, S. M., Wegner, N. J., Fossum, C. C., Wang, K., & Diasio, R. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3858 · Cited by 121
Kuilenburg, A. B. P., Meijer, J., Mul, A. N. P. M., Meinsma, R., Schmid, V., Dobritzsch, D., Hennekam, R. C. M., Mannens, M. M. A. M., Kiechle, M. B., Étienne-Grimaldi, M.-C., et al. (2010) · Human Genetics · doi:10.1007/s00439-010-0879-3 · Cited by 116
Capitain, O., Boisdron‐Celle, M., Poirier, A.-L., Abadie‐Lacourtoisie, S., Morel, A., & Gamelin, E. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500476 · Cited by 111
Germline Genetic Variation, Cancer Outcome, and Pharmacogenetics
Coate, L. E., Cuffe, S. D., Horgan, A. M., Hung, R. J., Christiani, D. C., & Liu, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2336 · Cited by 73
Ezzeldin, H. H., Johnson, M. R., Okamoto, Y., & Diasio, R. B. (2003) · PubMed · Cited by 71
Jennings, B. A., Loke, Y. K., Skinner, J. S., Keane, M., Chu, G. S., Turner, R., Epurescu, D., Barrett, A., & Willis, G. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078053 · Cited by 47
Steiner, M., Seule, M. A., Steiner, B., Bauer, I., Freund, M., Köhne, C.-H., & Schuff‐Werner, P. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.022319 · Cited by 37
Cited by
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.911 · Cited by 694
Self-citationHenricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G.-J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30686-7 · Cited by 444
Self-citationMeulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., Largiadèr, C. R., Jennings, B. A., Marinaki, A. M., Sanderson, J. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00286-7 · Cited by 381
Self-citationColon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 371
Metadata
- Authors
- Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H., Smits, P. H., Rosing, H., Mandigers, C. M. P. W., Soesan, M., Beijnen, J. H., & Schellens, J. H. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-01-20
- Volume
- 34
- Issue
- 3
- Pages
- 227-234
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2174633205
- Cited by
- 360
- References
- 25
- FWCI
- 32.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.